Frontage Holdings Corporation (“Frontage Holdings” or “Frontage,” stock code: 1521.HK), a Contract Research Organization (“CRO”) providing integrated, science-driven research, analytical and product development services in both the U.S. and China, announced today the opening of a new lab facility in Shanghai, China.
Thank you for registering!
You may now view the resource below.
Frontage’s newest facility in Hayward, CA started operations in 2022. With over 19,000 in. square footage, it supports bioanalytical and biologics projects. The Biologics Services Department provides exploratory and GLP-compliant Ligand Binding Assay (LBA) services to biotech and pharmaceutical industries, supporting pharmacokinetics (PK), immunogenicity (ADA), and biomarker analysis for protein therapeutics. The Bioanalytical Services Department provides R&D and GLP-compliant, quantitative mass spectrometry services to biotech and pharmaceutical industries, supporting all preclinical and clinical PK / TK / DDI / BA / BE, protein binding, and biomarker studies.
Frontage Virtual Tour: Do a 3D walkthrough of our site at 760 Pennsylvania Dr, Exton, PA 19341. In 2021 we opened our new 71,000-square-foot laboratory facility in Exton, PA. This new location supports our Bioanalytical, CMC, and Central Lab businesses. Our Bioanalytical suites focus on large molecules, biomarkers, and genomics. Our CMC laboratories feature a large analytical automation lab for small and large molecules, microbiology, and cell-based assays. Our large central laboratory includes a dedicated histology and pathology suite.
Frontage offers comprehensive expertise across a wide spectrum of projects from stand-alone exploratory toxicology to fully integrated IND programs, including general toxicology, safety pharmacology, and genetic toxicology.